ATE179712T1 - Analoge für spezifische oligosaccharid-protein- wechselwirkungen und ihre verwendungen - Google Patents

Analoge für spezifische oligosaccharid-protein- wechselwirkungen und ihre verwendungen

Info

Publication number
ATE179712T1
ATE179712T1 AT94910755T AT94910755T ATE179712T1 AT E179712 T1 ATE179712 T1 AT E179712T1 AT 94910755 T AT94910755 T AT 94910755T AT 94910755 T AT94910755 T AT 94910755T AT E179712 T1 ATE179712 T1 AT E179712T1
Authority
AT
Austria
Prior art keywords
methods
compositions
analogs
protein interactions
agonists
Prior art date
Application number
AT94910755T
Other languages
English (en)
Inventor
Daniel P Witt
Walter C Herlihy Jr
Original Assignee
Glycan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycan Pharm Inc filed Critical Glycan Pharm Inc
Application granted granted Critical
Publication of ATE179712T1 publication Critical patent/ATE179712T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5421—IL-8
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT94910755T 1993-03-01 1994-02-28 Analoge für spezifische oligosaccharid-protein- wechselwirkungen und ihre verwendungen ATE179712T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2455893A 1993-03-01 1993-03-01

Publications (1)

Publication Number Publication Date
ATE179712T1 true ATE179712T1 (de) 1999-05-15

Family

ID=21821208

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94910755T ATE179712T1 (de) 1993-03-01 1994-02-28 Analoge für spezifische oligosaccharid-protein- wechselwirkungen und ihre verwendungen

Country Status (7)

Country Link
US (1) US5795860A (de)
EP (2) EP0688327B1 (de)
AT (1) ATE179712T1 (de)
AU (1) AU6353294A (de)
CA (1) CA2157388C (de)
DE (1) DE69418322D1 (de)
WO (1) WO1994020512A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264709B1 (it) * 1993-07-12 1996-10-04 Italfarmaco Spa Derivati eparinici ad attivita' antimetastatica
US6277874B1 (en) * 1996-07-09 2001-08-21 University Of Cincinnati And Apologic, Incorporated Methods for the treatment of apolipoprotein E related diseases
AU3596797A (en) 1996-07-09 1998-02-02 Keith A. Crutcher Methods for the treatment of apolipoprotein e related diseases
US6989435B2 (en) * 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US6399078B1 (en) * 1998-06-01 2002-06-04 University Of Maryland Biotechnology Institute Chemokine—glycosaminoglycan complexes and their use in treating or preventing receptor mediated diseases
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
GB9913415D0 (en) * 1999-06-10 1999-08-11 Central Manchester Healthcare Heparanase assay
US6472436B1 (en) * 2000-07-17 2002-10-29 The Salk Institute For Biological Studies Methods for protecting cells from amyloid toxicity and for inhibiting amyloid protein production
US8314060B2 (en) * 2000-09-05 2012-11-20 Biosight Ltd. Peptide conjugated anti-cancer prodrugs
WO2002020715A2 (en) * 2000-09-05 2002-03-14 Biosight Ltd. Peptide conjugated anti-cancer prodrugs
AU2002351576A1 (en) * 2001-12-13 2003-07-09 Ism Biopolymer Inc. Method of modulating release of saccharides and uses thereof
CH696701A5 (de) * 2001-12-18 2007-10-15 Hoffmann La Roche Verfahren zum Testen eines Mittels auf dessen Fähigkeit, die Heparanaseaktivität zu hemmen.
DE10258770B4 (de) * 2001-12-18 2005-02-10 F. Hoffmann-La Roche Ag Verfahren zum Testen eines Mittels auf dessen Fähigkeit, die Heparanaseaktivität zu hemmen
GB0216861D0 (en) * 2002-07-19 2002-08-28 Univ Birmingham Saccharide libraries
US7795039B2 (en) * 2003-06-10 2010-09-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Electronic device for communication with living cells
US20060183712A1 (en) * 2005-02-17 2006-08-17 The Texas A&M University System Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826827A (en) * 1979-10-05 1989-05-02 Choay S.A. Short chained oligosaccharides having biological properties, a process for making the same and the use thereof as drugs
US5262403A (en) * 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
EP0337327A1 (de) * 1988-04-09 1989-10-18 Bioiberica, S.A. Verfahren zur Herstellung von neuen Oligosaccharid-Fragmenten durch kontrollierte chemische Depolymerisation von Heparin
WO1990003190A1 (en) * 1988-09-29 1990-04-05 Ranney David F Methods and compositions for magnetic resonance imaging
US5032679A (en) * 1988-12-15 1991-07-16 Glycomed, Inc. Heparin fragments as inhibitors of smooth muscle cell proliferation
US5380716A (en) * 1988-12-15 1995-01-10 Glycomed, Inc. Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
EP0477195A1 (de) * 1989-06-16 1992-04-01 The Upjohn Company Verbindungen des suramin-typs und angiostatische steroide zur verhütung der angiogenesis
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5116483A (en) * 1989-11-06 1992-05-26 Massachusetts Institute Of Technology Comb for affinity co-electrophoresis
US5079228A (en) * 1990-02-05 1992-01-07 Board Of Regents, The University Of Texas System Peptide inhibitors of neutrophil activating factor induced chemotaxis
US5158940A (en) * 1990-02-14 1992-10-27 The United States Government As Represented By The Secretary, Dhhs Use of suramin to treat rheumatologic diseases
AU7478191A (en) * 1990-03-05 1991-10-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Endogenous, suramin-induced, sulfated glycosaminoglycans as anti-cancer agents in humans
DK0454220T3 (da) * 1990-04-23 1993-11-22 Sanofi Elf Carbohydratderivater omfattende en trisaccharidenhed
WO1991019501A1 (en) * 1990-06-15 1991-12-26 Cytel Corporation Intercellular adhesion mediators
US5164295A (en) * 1991-03-06 1992-11-17 The Upjohn Company Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds
US5166137A (en) * 1991-03-27 1992-11-24 Nobipols Forskningsstiftelse Guluronic acid polymers and use of same for inhibition of cytokine production
MX9201801A (es) * 1991-04-16 1992-10-30 Seikagaku Kogyo Co Ltd Oligosacarido que tiene afinidad para el factor de desarrollo del fibroplasto y procedimiento para producirlo.
EP0509120B1 (de) * 1991-04-18 1996-07-17 LABORATORI BALDACCI Spa Topische Anwendung von Glycosaminoglykane zur Prävention und Behandlung der Zervikal- oder Vaginalerkrankungen
US5807982A (en) * 1991-04-29 1998-09-15 Cornell Research Foundation, Inc. Affinity purified heparin
IL102758A (en) * 1991-08-23 1997-03-18 Akzo Nv Glycosaminoglycanoid derivatives, their preparation and pharmaceutical compositions comprising them
WO1993007864A1 (en) * 1991-10-23 1993-04-29 British Technology Group Ltd. Use of suramine and related compounds as contraceptive agents
AU673506B2 (en) * 1991-11-14 1996-11-14 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors and methods for preventing or reducing scarring
EP0636175A1 (de) * 1992-04-03 1995-02-01 La Jolla Cancer Research Foundation Decorin-fragmente und verfahren zur zell-regulationfaktoren-inhibierung

Also Published As

Publication number Publication date
US5795860A (en) 1998-08-18
CA2157388A1 (en) 1994-09-15
DE69418322D1 (de) 1999-06-10
WO1994020512A3 (en) 1994-11-24
EP0900804A2 (de) 1999-03-10
EP0688327A1 (de) 1995-12-27
AU6353294A (en) 1994-09-26
CA2157388C (en) 1998-12-15
EP0688327B1 (de) 1999-05-06
WO1994020512A2 (en) 1994-09-15

Similar Documents

Publication Publication Date Title
DE69418322D1 (de) Analoge für spezifische oligosaccharid-protein-wechselwirkungen und ihre verwendungen
ATE302278T1 (de) Diagnose und behandlung von aur1 und/oder aur2 verwandten erkrankungen
DE69635740D1 (de) Diagnose und behandlung von mit aur-1 und/oder aur-2 assoziierten erkrankungen
DE68922065D1 (de) Verbesserte Packung für chirurgisches Nahtmaterial.
ATE239079T1 (de) Gewebeinhibitor für metalloproteasen type 3 (timp-3)
DE69728149D1 (de) Modifizierte liganden für den tie-2-rezeptor
RU94022254A (ru) Лиганды, содержащие гетероатом, их комплексы с металлами, способ получения, способ лечения и применение в диагностических наборах
DE60005100D1 (de) Selektion von zielregionen für zink-finger-proteine und methoden zum design von zink-finger-proteinen welche an vorselektierte regionen binden
TR199901949T2 (xx) Lemfositik t�m�rler i�in �areler.
ES2153671T3 (es) Peptidos neuroactivos.
DE69510810D1 (de) Lamanin-ketten: diagnostische und therapeutische verwendung
DE69636720D1 (de) Dem fibroblasten wachstumsfaktor homologer faktor-1(fhf-1) und methoden zu seiner verwendung
EP0787207A4 (de) Neue methode zum auffindenund bewerten biologisch aktiver moleküle
DE3885969D1 (de) Neue 6-Acyl-(6H)-dibenz[c,e] [1,2]oxaphosphorin-6-oxyde, ihre Herstellung und Verwendung als Photoinitiatoren.
MXPA02008239A (es) Gen humano de la esquizofrenia.
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
EE05497B1 (et) Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
ATE196775T1 (de) Gereinigte flt3 liganden von saeugentieren, agonisten und antagonisten davon
HUP9900506A2 (hu) Protrombinszármazékok
ATE120494T1 (de) Fibronectinbindungsprotein und dessen herstellung.
DE3873524D1 (de) Iodierte polymere, verfahren zu ihrer herstellung und ihre verwendung als kontrastmittel.
TR199801659T2 (xx) Yeni triazolopurinler, haz�rlama y�ntemi, ila� olarak kullan�m�.
DK0649433T3 (da) Antigeniske regioner fra komplekser af tumorfrigivne partikler (TLP) og antistoffer mod sådanne.
ATE317021T1 (de) Antisense modulierung von lfa-3
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties